Huppke, Brenda

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Toxicology"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Kilian, Adrienne"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Groeneveld, Annette"],["dc.contributor.author","Schaper, Andreas"],["dc.date.accessioned","2018-11-07T10:20:30Z"],["dc.date.available","2018-11-07T10:20:30Z"],["dc.date.issued","2016"],["dc.format.extent","381"],["dc.identifier.isi","000374999800032"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41905"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Ltd"],["dc.publisher.place","Abingdon"],["dc.relation.issn","1556-9519"],["dc.relation.issn","1556-3650"],["dc.title","Phenethylamines - they have known, but have they loved? Mass intoxication with 2C-E in northern Germany"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","382"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Multiple Sclerosis"],["dc.bibliographiccitation.lastpage","387"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Hummel, Hannah-Maria"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Pfeifenbring, Sabine"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:44:28Z"],["dc.date.available","2017-09-07T11:44:28Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Because of the emergence of novel therapies for multiple sclerosis (MS) and the associated increased risk of progressive multifocal leukoencephalopathy, John Cunningham (JC) virus infection has become a focus of interest for neurologists. However, little is known about JC virus infection in pediatric MS to date. Objective: We aimed to analyze the prevalence of anti-JC virus antibodies, the conversion rate and the influence of the anti-JC virus antibody status on the clinical course in a large pediatric MS cohort. Methods: Anti-JC virus antibodies were analyzed in serum samples within six months of disease onset and during the course of the disease. Clinical data were extracted from a pediatric MS databank. Results: A total of 51.6% of 256 patients were found to be positive for anti-JC virus antibodies at onset of disease. No correlation between antibody status and clinical course was seen. Analyzing 693 follow-up serum samples revealed high titer stability, and an annual conversion rate of 4.37% was seen. Conclusion: No evidence was found that seropositivity for anti-JC virus antibodies influences the clinical course. Surprisingly, seroprevalence for anti-JC virus antibodies was more than twice as high as anticipated in this age group, raising the question of whether the infection increases the risk of MS development."],["dc.identifier.doi","10.1177/1352458514543340"],["dc.identifier.gro","3141931"],["dc.identifier.isi","000352165000006"],["dc.identifier.pmid","25070674"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2668"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","JC virus antibody status in a pediatric multiple sclerosis cohort: Prevalence, conversion rate and influence on disease severity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","232"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Pediatric Neurology"],["dc.bibliographiccitation.lastpage","234"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Heise, Alexander"],["dc.contributor.author","Rostasy, Kevin"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:46:52Z"],["dc.date.available","2017-09-07T11:46:52Z"],["dc.date.issued","2009"],["dc.description.abstract","Idiopathic hypothalamic dysfunction is a rare disorder presenting at age 3-7 years. Severe hypothalamic and brainstem dysfunction leads to death in 25% of patients. The disease is presumed to be autoimmune, or in some cases paraneoplastic. No successful treatment has been reported. Patient V. developed hyperphagia, hypersomnia, and extreme aggression at age 7 years, accompanied by episodes of hyperthermia, hypothermia, sinus bradycardia, hypernatremia, hyponatremia, persistent hyperprolactinemia, hypothyroidism, and growth-hormone deficiency. At age 9 years, a diagnosis of idiopathic hypothalamic dysfunction was rendered, and immunoglobulin therapy was commenced. Nine courses of immunoglobulins, at a dose of 2 g/kg every 4 weeks, were administered. Reproducible improvements in behavior and no further episodes of hyponatremia or hypernatremia and sinus bradycardia were evident. The endocrinologic abnormalities and poor thermoregulation remained. Administration of immunoglobulins during late stages of idiopathic hypothalamic dysfunction led to improvement in some but not all signs. Assuming an autoimmune basis for this disorder, treatment during early stages of disease should be more effective. To facilitate such early treatment, increased awareness of this disorder is necessary, to allow for early diagnosis. (C) 2009 by Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.pediatrneurol.2009.03.017"],["dc.identifier.gro","3143067"],["dc.identifier.isi","000268866200018"],["dc.identifier.pmid","19664546"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/540"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0887-8994"],["dc.title","Immunoglobulin Therapy in Idiopathic Hypothalamic Dysfunction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1655"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Archives of Neurology"],["dc.bibliographiccitation.lastpage","1658"],["dc.bibliographiccitation.volume","65"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Zuercher, Claudia"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:48:08Z"],["dc.date.available","2017-09-07T11:48:08Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: Natalizumab, a humanized monoclonal antibody raised against alpha(4) integrins, is approved for treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients. Objective: To determine the safety, effectiveness, and tolerability of natalizumab use in pediatric patients with MS. Design: Case report. Setting: Center for MS in childhood and adolescents, Gottingen, Germany. Patients: Three pediatric patients with RRMS having a poor response to other immunomodulatory therapies or having intolerable adverse effects. Interventions: Natalizumab given every 4 weeks at a dosage of 3 to 5 mg/kg of body weight. Main Outcome Measures: Cranial magnetic resonance (MR) imaging before treatment and every 6 months thereafter. Results: During 24, 16, and 15 months of treatment, no further relapses occurred in the 3 pediatric patients; all reported significant improvement in their quality of life. Follow-up MR imaging showed no new T2-weighted lesions or gadolinium-enhancing lesions. No adverse events were seen when dosage was adjusted to body weight. Conclusions: Natalizumab treatment was effective and well tolerated in our pediatric patients with RRMS who did not respond to initial immunomodulatory treatments. Therefore, it is a promising second-line therapy for pediatric patients with RRMS."],["dc.identifier.doi","10.1001/archneur.65.12.1655"],["dc.identifier.gro","3143197"],["dc.identifier.isi","000261483100015"],["dc.identifier.pmid","19064754"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/685"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Amer Medical Assoc"],["dc.relation.issn","0003-9942"],["dc.title","Natalizumab Use in Pediatric Multiple Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1157"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","JAMA Neurology"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Hummel, Hannah-Maria"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Röbl, Markus"],["dc.contributor.author","Gärtner, Jutta"],["dc.contributor.author","Huppke, Peter"],["dc.date.accessioned","2020-04-02T09:57:28Z"],["dc.date.available","2020-04-02T09:57:28Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1001/jamaneurol.2019.1997"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/63492"],["dc.relation.issn","2168-6149"],["dc.title","Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","441"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal of Neurology"],["dc.bibliographiccitation.lastpage","446"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Rosewich, Hendrik"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Gärtner, Jutta"],["dc.contributor.author","Huppke, Peter"],["dc.date.accessioned","2017-09-07T11:46:28Z"],["dc.date.available","2017-09-07T11:46:28Z"],["dc.date.issued","2014"],["dc.description.abstract","Background and purposeMultiple sclerosis (MS) onset before puberty is extremely rare and establishment of diagnosis is often difficult due to atypical presentation. The study aims to identify the typical presentation of MS in this age group. MethodsPediatric MS patients were identified from the database of the Center for Multiple Sclerosis in Childhood and Adolescence at the University Medical Center Gottingen, Germany. Inclusion criteria were a relapsing-remitting initial disease course and minimum disease duration of 4years. ResultsForty-seven pre-pubertal (<11years) and 41 post-pubertal (14-16years) MS patients were compared. Before puberty an even gender ratio was found. The pre-pubertal patients were more likely to have a polysymptomatic severe first attack with motor and brainstem involvement, sphincter dysfunction, cognitive disturbances and milder residual neurological sequelae after the first episode whilst the post-pubertal patients predominantly presented with optic neuritis and sensory symptoms. The initial symptom pattern prevailed over the first 2years of disease. Presentation of pre-pubertal boys and girls did not differ significantly. ConclusionsTo facilitate early diagnosis it is important to recognize that pre-pubertal MS presents with a specific pattern of symptoms that is maintained over the first two disease years."],["dc.identifier.doi","10.1111/ene.12327"],["dc.identifier.gro","3142181"],["dc.identifier.isi","000330976200013"],["dc.identifier.pmid","24330201"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5432"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley-blackwell"],["dc.relation.eissn","1468-1331"],["dc.relation.issn","1351-5101"],["dc.title","Clinical presentation of pediatric multiple sclerosis before puberty"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]